Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer

Judith E Karp^{1

2}, Antonio C Wolff¹

Affiliations

¹ Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
² Department of Medicine, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Editorial

Judith E Karp et al. Cancer. 2016.

. 2016 Jan 15;122(2):178-80.

doi: 10.1002/cncr.29613. Epub 2015 Dec 7.

Judith E Karp^{1

2}, Antonio C Wolff¹

¹ Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
² Department of Medicine, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

No abstract available

Comment on

Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, Larson RA. Churpek JE, et al. Cancer. 2016 Jan 15;122(2):304-11. doi: 10.1002/cncr.29615. Epub 2015 Dec 7. Cancer. 2016. PMID: 26641009 Free PMC article.

1. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer. 2007;7:152. doi: 10.1186/1471-240-7-7-152. - DOI - PMC - PubMed
1. Gale RP, Bennett JM, Hoffman FO. Therapy-related AML: a slip of the lip can sink a ship. Leukemia Research. 2014;38:418–20. - PubMed
1. Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the National Comprehensive Cancer Network experience. J Clin Oncol. 2015;33(4):340–8. - PMC - PubMed
1. Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ. Therapy-related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat. 2009;118(3):593–8. - PMC - PubMed
1. Schulz E, Valentin A, Utz P, et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy-related myeloid neoplasms. J Med Genet. 2012;49(7):422–8. - PubMed